Media stories about Emergent Biosolutions (NYSE:EBS) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Emergent Biosolutions earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.0862440947485 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Emergent Biosolutions (EBS) opened at $38.34 on Friday. Emergent Biosolutions has a 52 week low of $25.96 and a 52 week high of $44.86. The firm has a market cap of $1,587.93, a price-to-earnings ratio of 20.30, a P/E/G ratio of 1.06 and a beta of 1.22. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The business had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. During the same quarter last year, the firm earned $0.56 earnings per share. Emergent Biosolutions’s quarterly revenue was up 4.6% on a year-over-year basis. analysts expect that Emergent Biosolutions will post 1.64 EPS for the current fiscal year.
Several equities analysts have recently issued reports on the stock. BidaskClub downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Finally, Zacks Investment Research raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research note on Wednesday, October 25th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Emergent Biosolutions presently has a consensus rating of “Buy” and an average target price of $45.00.
COPYRIGHT VIOLATION WARNING: “Emergent Biosolutions (EBS) Getting Somewhat Favorable Press Coverage, Report Shows” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/17/emergent-biosolutions-ebs-getting-somewhat-favorable-press-coverage-report-shows.html.
In other Emergent Biosolutions news, Director Ronald Richard sold 22,415 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $40.00, for a total value of $896,600.00. Following the completion of the sale, the director now directly owns 24,676 shares in the company, valued at $987,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Adam Havey sold 7,885 shares of the firm’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $37.06, for a total transaction of $292,218.10. Following the completion of the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,257,482.86. The disclosure for this sale can be found here. Insiders have sold 255,210 shares of company stock valued at $10,157,974 in the last three months. 16.50% of the stock is owned by insiders.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.